Chronic kidney disease (CKD) is a major concern in public health. The pathology of CKD includes premature ageing in the kidney and vessels, which results in a high risk of cardiovascular events and end-stage renal disease. Many factors are involved in premature ageing in CKD, including hormonal imbalance, glycative stress, nitrogenous metabolites, and oxidative stress. Of these, the most important role in premature ageing in CKD is played by glycative stress, namely a massive and unfavourable glycation state, since the kidney is responsible for the clearance of advanced glycation endproducts (AGEs). In an animal model, overexpression of glyoxalase I (GLO-1), a detoxifier of AGEs, has been found to alleviate premature ageing in the kidney and vessels. Both lifestyle changes and drug therapy have shown promise in overcoming premature ageing. Promising drug therapies include a GLO-1 activator and an absorbent against glycotoxin and nitrogenous metabolites.
| THE IMPORTANCE OF CHRONIC KIDNEY DISEASE IN PUBLIC HEALTH
The diagnosis of chronic kidney disease (CKD) is based on the presence of abnormalities in kidney structure or function that are present for more than 3 months, and have implications for health. Diagnosis often includes the presence of persistent proteinuria and/or decreased glomerular filtration rate. The importance of CKD as a disease entity is high in patients at a high risk of developing cardiovascular disease and end-stage renal disease.
1 CKD is frequent not only in developed but also in developing countries, indicating that it will be an even greater important public health problem in the future. 2 Moreover, medical care costs are higher when CKD is present even in its early stage. 3 Thus, a clear understanding of the mechanism and complications of CKD is a critical public health measure. CKD itself and many CKD complications such as frailty, muscle wasting, cardiovascular disease, and osteoporosis, can be understood as symptoms of premature ageing. [4] [5] [6] Thus, accurate appreciation of premature ageing should be beneficial for the treatment of complications of CKD. In this review, we provide detailed description of the pathophysiology of premature ageing, especially the role of glycative stress, and therapeutic approaches against glycative stress in CKD.
| PREMATURE AGEING IN CHRONIC KIDNEY DISEASE
Chronic kidney disease patients frequently show a phenotype of systemic premature ageing, including frailty, muscle wasting, osteoporosis, and cardiovascular disease ( Figure 1 ). 4 One clear piece of evidence for premature ageing in CKD patients is the shortening of telomere length. The shortening of telomere length is often seen in peripheral blood mononuclear cells of haemodialytic patients, 7 and the length of telomeres is correlated with CKD progression and cardiovascular disease risk in CKD patients. 8, 9 Ageing of stem cells is also seen in animal models of CKD. Mesenchymal stem cells (MSCs) in the bone marrow also show premature ageing. 10 Klinkhammer et al. reported that MSCs from remnant kidney model rats and rats with adenine nephropathy present a premature ageing phenotype, such as active senescenceassociated-β-galactosidase (SA-β-gal), accumulation of actin, and a modulated secretion profile. That report also implicated some humoral abnormalities or an increase in uremic toxins as responsible for systemic premature ageing. Indeed, MSCs from human muscle present ageing phenotypes, including an increase in SA-β-gal, p53, and p21, in addition to fibroblast growth factor 23 (FGF-23), which functions as a phosphaturic hormone and is elevated in CKD patients. 11, 12 As such, these findings might partly explain the muscle wasting seen in CKD.
Recently, another mechanism of muscle wasting in CKD has been proposed. Using fat-specific parathyroid hormone (PTH) receptor knockout mice, Kir et al. reported that PTH, as well as PTH-related protein (PTHrP), induce hypercatabolism and sarcopenia via PTH receptors in fat tissues in mice. 13, 14 They also showed the existence of a similar reaction, namely adipose tissue browning, even in patients with primary hyperparathyroidism. However, the link between adipose tissue response to PTH/PTHrP and muscle wasting has not been elucidated.
Adipose tissue browning has been proven beneficial in another metabolic disease, 15 and further detailed research into the specific mechanism of PTH's induction of muscle wasting in CKD is warranted.
The role of CKD in accelerating atherosclerosis is widely known.
The hallmarks of atherosclerosis in CKD are increases in arterial diameter and intima-media thickness; in atherosclerosis, the process of ageing differs from normal ageing, which is characterized by arterial enlargement, wall thickening, and stiffening. 16, 17 The mechanism of premature ageing in CKD is multifactorial, although humoral factors in particular are thought to play an import- with a decrease in glomerular filtration rate (GFR). 24 In humans, the kidneys of end-stage renal disease patients may contain less klotho F I G U R E 1 Chronic kidney disease (CKD) and premature ageing phenotype. CKD is related to frailty, osteoporosis, muscle wasting, and cardiovascular diseases. The causes of premature ageing in CKD are wide-ranging; representative causes include shortening of telomere length, stem cell ageing, uremic toxins, and humoral disorders protein than the kidneys of non-CKD patients, but the evidence for this is fragile. 25, 26 In contrast, the kidneys of two different rat CKD models were proven to contain less klotho protein than those of the corresponding control group. 25, 27 These results suggest that renal klotho protein expression is downregulated in CKD. One plausible evidence for this involves epigenetic change by uremic toxins; Sun et al. reported that the representative uremic toxins indoxyl sulphate and ρ-cresyl sulphate induce an increase in klotho gene hypermethylation. 28 Decreased klotho expression is considered to be related to premature ageing. The mechanism of decrease klotho expression in CKD warrants further research.
| Angiotensin II
Angiotensin II (AngII) is known to be an ageing-promoting factor, and the production of AngII is increased in CKD. 29 AngII is known to induce premature ageing in vascular smooth muscle cells via a p21-dependent pathway and partly via telomere length shortening. 30, 31 AngII also has an effect on muscle wasting. 32, 33 Since the rennin-angiotensin-aldosterone system is activated not only in CKD, but also in other chronic diseases such as chronic heart failure and chronic obstructive pulmonary disease, 6 AngII is considered to act as a key hormone that causes premature ageing in various chronic diseases.
| IMPORTANCE OF RENAL HYPOXIA AND OXIDATIVE STRESS IN PREMATURE AGEING IN CKD
Since oxygen is a vital molecule for energy production in metazoans, cells and tissues immediately react to intracellular oxygen reduction.
Hypoxia-inducible factors (HIFs) are located central to such reactions. 34 HIFs consist of two subunits, HIF-α and HIF-β. Among these, HIF-α is an oxygen sensitive subunit and undergoes hydroxylation via prolyl hydroxylase, resulting in proteasomal degradation in normoxic conditions. Once intracellular oxygen tension decreases, hydroxylation of HIF-α stops, and HIF-α accumulates in the cytosol and forms a heterodimer with HIF-β. Finally, this heterodimer binds to enhancer regions of several genes and promotes their transcription.
It is widely known that partial pressure of oxygen in the kidney is relatively low under physiological conditions. The cause of this is multifactorial: one representative reason is the existence of an arteriovenous oxygen shunt inside the kidney. 35 In CKD patients, renal oxygen tension decreases further, and the lower oxygen tension in turn exacerbates CKD progression. 36, 37 Representative mechanisms of this exacerbation include rarefaction of peritubular capillaries, increased oxygen demand in tubules, and anemia. In contrast, renal hypoxia also exacerbates CKD progression via a mechanism involving oxidative stress, since hypoxia itself induces oxidative stress, which is related to premature ageing. 38, 39 Finally, ageing itself also decreases renal oxygen tension. 40 Thus, CKD, renal hypoxia, and renal senescence interact with each other (Figure 2 ).
| THE ROLE OF UREMIC TOXINS IN PREMATURE AGEING IN CKD

| AGE precursors
Glycation is the non-enzymatic modification of a protein by glucose.
A glycated protein is divided into three groups: the Schiff base, the Amadori rearrangement compound, and the advanced glycation end product. 41 The condition of increased concentration of glycated protein is termed glycative stress. Unlike the other two subgroups,
AGEs are stable and irreversible compounds, and are harmful to living organs. Several AGE precursors accumulate in the body as CKD progresses, including methylglyoxal and glyoxal, which are reactive carbonyl compounds derived mainly from carbohydrates. These also exacerbate CKD. Since AGEs are harmful, living organisms have systems to eliminate them-detoxifier enzymes including glyoxalase-1 (GLO-1) and excretion via the urine. The production of AGEs is related to the extent of oxidative stress as well as blood glucose level, 42 and
AGEs also increase oxidative stress via their receptor, RAGE (receptor for AGEs). 43 Thus, AGEs and oxidative stress are mutually promoted.
The notion that AGEs are closely related to ageing first arose from an examination of the longevity of Caenorhabditis elegans, which showed that GLO-1 overexpression prolonged longevity and reduced the production of reactive oxygen species (ROS) in this species. 44, 45 AGEs and GLO-1 have now achieved wide acceptance as important molecules in ageing.
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As described previously, the kidney plays a role in AGE clearance.
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Moreover, oxidative stress is increased in CKD patients, 48 resulting in an additional increase in AGE accumulation (Figure 3 ). On the other hand, the kidney is one of the major organs affected by AGE injury. In 1994, Vlassara et al. reported that AGE-albumin administration resulted in albuminuria and histological changes, such as glomerulosclerosis, 49 proving that AGEs damage the kidney. Vascular ageing is a major phenotype
The vicious cycle between Chronic kidney disease (CKD) progression, renal hypoxia, and renal premature senescence. CKD progression exacerbates renal hypoxia via capillary rarefaction, increased tubular oxygen demand, and the existence of anemia. Hypoxia is closely related to oxidative stress, which accelerates premature ageing of CKD, and AGEs also induce vascular calcification and endothelial dysfunction. 50, 51 The importance of glycative stress for the development of vascular complications is also proven in clinical patients. Genuth et al.
reported that skin collagen glycation is correlated with long-term risk for diabetic complications. 52 Recently, skin autofluorescence, which reflects the extent of skin collagen glycation, is reported to be a predictor of all-cause mortality in CKD patients. 53 These results clarify that there is close relationship between the phenotype of CKD and systemic glycative stress. Thus, AGEs act as uremic toxins, and account for several aspects of the systemic premature ageing of CKD.
| Indoxyl sulphate
Indoxyl sulphate, which is converted from its precursor indole in the gastrointestinal tract, is a representative uremic toxin derived from amino acid metabolism. 54 This metabolite came into focus following confirmation of its relationship to CKD progression in patients with decreased eGFR. 55 One means of examining the effect of indoxyl sulphate is by examining the effect of AST-120, an oral absorbent of uremic toxins, including indoxyl sulphate. In remnant kidney model rats, the aorta displays a premature ageing phenotype, including increases in p21, p53, and SA-β-gal. Because oral administration of AST-120 alleviates these phenotypic changes, indoxyl sulphate is accordingly considered to exacerbate premature vascular ageing in CKD. 56 AST-120 also reduces the phosphorylation of the tubular signal transducer and activator of transcription 3 (Stat3) in remnant kidney model rats. In cultured cell experiments, Stat3 is involved with the indoxyl sulphate-induced accumulation of SA-β-gal. These results indicate that indoxyl sulphate induces tubular senescence in vivo, and that a reduction in indoxyl sulphate must likely have positive effects in tubular premature ageing. 57 Indoxyl sulphate also promotes premature ageing via its inhibition of erythropoiesis. Chiang et al. reported that indoxyl sulphate suppresses erythropoietin production via inhibition of the nuclear accumulation of HIF-α. 58 Given that a reduced hematocrit leads to the aggravation of tubular hypoxia, 59 this effect of indoxyl sulphate also promotes renal hypoxia in CKD.
| ROLE OF GLO-1 IN PREMATURE AGEING BY GLYCATIVE STRESS
As described previously, GLO-1 is a powerful detoxifier of glycative stress, and enhancing its activity appears to be a promising strategy against premature senescence in CKD. Kumagai However, whether GLO-1 is protective against other aspects of the premature ageing phenotype seen in CKD, such as frailty, muscle wasting and/or osteoporosis, has not been clarified.
| PREVENTION OF PREMATURE AGEING IN CKD
| Dietary habits
Unhealthy lifestyle behaviours have been reported as a risk factor of CKD. In fact, Michishita et al. demonstrated that a lack of habitual F I G U R E 3 Differences in the dynamics of AGEs between healthy subjects and CKD patients. In healthy subjects, AGEs are cleared by the kidneys or by GLO-1, and the concentration of AGEs is generally so low that the cytotoxicity of AGEs does not matter. In contrast, the concentration of AGEs in serum or tissue is often increased, because of increased AGE production, reduced renal clearance, and reduced GLO-1 enzymatic activity. AGEs are proven to be cytotoxic in the kidneys; thus, AGEs work as uremic toxins moderate exercise and the consumption of a late-night dinner and bedtime snacking may be associated with the prevalence of CKD. 63 Certain dietary habits are key contributors to the high levels of AGEs in our body. High AGEs are produced when foods are cooked at a high temperature for a short time, as compared to when they are cooked at a low temperature over a long time. In addition, the frying of meats produces more AGEs than boiling or stewing them. 64 Further, low potassium and phosphorus diets alter the symbiotic bacterial profile in the gut, and thereby increase the production of plasma uremic toxins such as bacteria-derived metabolites, leading to CKD progression. 65 These findings strongly suggest that a healthy lifestyle, including good dietary habits, is absolutely critical to preventing CKD progression, namely premature kidney ageing.
| AGE inhibitors
Reducing uremic toxin levels in the body is also important in prevent- Pyridoxamine, which inhibits AGE formation by trapping AGE precursors, ameliorated albuminuria and redox imbalances in type 1 and type 2 diabetic nephropathy rodents. 66, 67 A phase 2 study revealed that pyridoxamine significantly reduced serum creatinine levels in a treatment group of patients with overt nephropathy and type 1 or type 2 diabetes.
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Another appealing approach to intervention is the inhibition of AGE-RAGE signal transduction. In type 1 diabetic OVE26 mice, RAGE knockout, which inhibits AGE-RAGE signalling, showed a renoprotective effect via a reduction in nephromegaly, mesangial sclerosis, cast formation, glomerular basement membrane thickening, podocyte effacement, and albuminuria. 69 In db/db mice, the neutralizing RAGE antibody that interferes with the binding of AGE with RAGE ameliorates urinary albumin excretion and serum creatinine levels, and maintains kidney weight, glomerular and mesangial volume. 
| Uremic toxin absorbent
Another approach for a reduction in uremic toxin level is the use of a uremic toxin adsorbent such as AST-120, as mentioned above. Clinical trials evaluating the reno protective effect of AST-120 in CKD patients remain controversial, and further investigation to prove that AST-120 suppresses CKD progression, as well as kidney ageing is necessary.
| Regulators for intestinal disorders
Reducing uremic toxin levels by suppressing uremic toxin production is also renoprotective. Substantial evidence shows that some uremic toxins, such as plasma indoxyl sulphate or ρ-cresyl sulphate, are metabolites produced by the gut microbiota, and that their alteration increases uremic toxin levels. Probiotics and prebiotics have been shown to restore the homeostasis of the gut microbiota and compromised kidney ageing. Probiotics may restore gut flora balance and prevent CKD by enhancing the gut barrier, suppressing pathobiont overgrowth, and improving anti-inflammatory effects and immunity tolerance. 72 However, prebiotics also provide benefits in preventing premature ageing of the kidney: administration of galactooligosaccharides to rats was found to modify the microbiota profile and ameliorate kidney damage. 73 Not only probiotics and prebiotics, but also lubiprostone, a ClC-2 chloride channel activator, was indicated to ameliorate the progression of CKD and the accumulation of uremic toxins by improving the gut microbiota and intestinal environment in mice. 74 Taken together, these findings shed light on potent new therapeutics for premature ageing of the kidneys that suppress uremic toxin accumulation by decreasing uremic toxin production.
| Nuclear respiratory factor (Nrf)-2 pathway activator
Adequately reducing the pathogenic stress, including oxidative stress, chronic inflammation, and glycative stress, is one of the promising strategies to prevent the premature ageing in CKD. In fact, bardoxolone methyl (RTA 402) activates the Nrf2 pathway and inhibits the NF-κB pathway, and subsequently improves renal function as evaluated by estimated glomerular filtration rate (eGFR). Previously, a phase 2 clinical study (the BEAM study) demonstrated that bardoxolone methyl increased the eGFR of CKD patients with type 2 diabetes. 75 Unfortunately, a phase 3 clinical trial (BEACON study) was terminated, due to safety concerns over an associated increase in heart failure.
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However, because of the relatively low incidence rate of cardiovascular events in Asia, a phase 2 clinical trial was re-started in Japan.
Interim analysis of this study in Japan showed that bardoxolone methyl Another strategy for activating Nrf2 is the inhibition of mechanistic target of rapamycin complex 1 (mTORC1). 79, 80 Inhibition of mTORC1 by rapamycin is proven to extend lifespan even in mice, 81, 82 and its suppression has been shown to result in the activation of Nrf2 translation, 83 which should ameliorate glycative stress via GLO-1 activation. Thus, mTORC1 inhibition is a candidate for pharmaceutical intervention against premature ageing in CKD patients. Metformin, a frequently-used anti-type 2 diabetes drug, is also proven to elongate the lifespan of C. Elegans via mTORC1 inhibition. 84 Thus, this drug might be effective against premature ageing in CKD, although it has one drawback, in that it cannot be used in cases of advanced CKD due to the risk of lactic acidosis.
| CONCLUSIONS
As stated above, CKD and premature ageing in CKD have become more important health problems in current society. High levels of FGF23 and angiotensin II are frequently detected in CKD patients, which accelerate premature ageing directly or via hyperphosphatemia and hypertension, respectively. In addition to increased levels of indoxyl sulphate in CKD patients, ageing itself induces renal hypoxia, 85 which in turn increases glycative stress via increased oxidative stress.
Thus, interventions targeting glycative stress, such as enforcing GLO-1 and reducing absorption of AGEs, are promising strategies.
The causes of premature ageing in CKD cover a broad range of topics, and therefore require not only an individual, but also a com-
prehensive understanding of what is needed in this field. Another problem is that, in clinical trials, ageing phenotype such as frailty and muscle wasting, are rarely set as outcomes, so an interventionwhether targeted towards premature ageing or not-is hardly judged to beneficial to premature ageing. Regardless, as premature ageing becomes increasingly important in the current society, further research and studies in this field, especially clinical trials that focus on the antiageing effect of the drugs described before, are needed.
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